natgillin/translations-raw huggingface dataset:
Both are medicines to lower the blood pressure that have been available in the European Union (EU) since the 1990s. 
Obe sta učinkovini za zniževanje krvnega tlaka, ki sta v Evropski uniji (EU) na voljo od devetdesetih let prejšnjega stoletja.
Because telmisartan and amlodipine have been used for many years, the company presented information from scientific literature as well as results from new studies that the company had carried out. 
Ker se telmisartan in amlodipin uporabljata že vrsto let, je družba predstavila informacije iz znanstvene literature, pa tudi rezultate novih študij, ki jih je izvedla.
The European Commission granted a marketing authorisation valid throughout the EU for Twynsta on 7 October 2010. 
Evropska komisija je dovoljenje za promet z zdravilom Twynsta, veljavno po vsej Evropski uniji, izdala 7. oktobra 2010.
It is available as tablets (40 mg telmisartan/10 mg amlodipine, 40 mg telmisartan/5 mg amlodipine, 80 mg telmisartan/10 mg amlodipine and 80 mg telmisartan/5 mg amlodipine). 
Na voljo je v obliki tablet (40 mg telmisartana/10 mg amlodipina; 40 mg telmisartana/5 mg amlodipina; 80 mg telmisartana/10 mg amlodipina; 80 mg telmisartana/5 mg amlodipina).
Other information about Twynsta: 
Druge informacije o zdravilu Twynsta:
Twynsta telmisartan / amlodipine 
Twynsta telmisartan/amlodipin
It blocks special channels on the surface of cells called calcium channels, through which calcium ions normally enter the cells. 
Povzroči zaporo posebnih kanalčkov na površini celic, imenovanih kalcijevi kanalčki, skozi katere v celico običajno vstopajo kalcijevi ioni.
This is a summary of the European public assessment report (EPAR) for Twynsta. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Twynsta.
The main measure of effectiveness in the three studies was the fall in diastolic blood pressure (blood pressure measured between two heartbeats) after eight weeks. 
Glavno merilo učinkovitosti v vseh treh študijah je bilo znižanje diastoličnega krvnega tlaka (krvnega tlaka, izmerjenega med dvema udarcema srca) po osmih tednih.
The Committee decided that Twynsta's benefits are greater than its risks and recommended that it be given marketing authorisation. 
Odbor je zaključil, da so koristi zdravila Twynsta večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
The full EPAR for Twynsta can be found on the Agency's website under EMA website/Find medicine/Human medicines/European Public Assessment Reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Twynsta je na voljo na spletni strani agencije under EMA website/Find medicine/Human medicines/European Public Assessment Reports.
For more information about treatment with Twynsta, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Twynsta preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
Telmisartan is an ‘angiotensin II receptor antagonist', which means that it blocks the action of a hormone in the body called angiotensin II. 
Telmisartan je antagonist receptorjev angiotenzina II, kar pomeni, da v telesu preprečuje delovanje hormona, imenovanega angiotenzin II.
Twynsta is used to treat essential hypertension (high blood pressure) in adults (aged 18 years or over). 
Zdravilo Twynsta se uporablja za zdravljenje esencialne hipertenzije (visokega krvnega tlaka) pri odraslih (starejših od 18 let).
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Twynsta. 
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil to zdravilo, na podlagi česar je oblikoval mnenje za izdajo dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
What benefit has Twynsta shown during the studies? 
Kakšne koristi je zdravilo Twynsta izkazalo med študijami?
The most common side effects with Twynsta (seen in up to 1 patient in 10) are dizziness and peripheral oedema (swelling, especially of the ankles and feet). 
Najpogostejša neželena učinka zdravila Twynsta (opažena pri več kot 1 bolniku od 10) sta omotica in periferni edem (otekanje, zlasti gležnjev in stopal).
Twynsta must not be used in people who may be hypersensitive (allergic) to telmisartan, amlodipine, other medicines in the ‘dihydropyridine derivatives' class or to any of the other ingredients. 
Zdravila Twynsta ne smejo uporabljati osebe, ki utegnejo biti preobčutljive za (alergične na) telmisartan, amlodipin, druga zdravila iz razreda „derivatov dihidropiridina“ ali katero koli drugo sestavino zdravila.
In addition, studies showed that the medicine was effective in patients whose blood pressure is not adequately controlled by amlodipine alone. 
Poleg tega so študije pokazale, da je bilo zdravilo učinkovito pri bolnikih, pri katerih krvni tlak ni bil zadostno uravnan samo z amlodipinom.
The CHMP noted that patients already taking the two active substances in separate tablets may be more likely to adhere to their treatment if prescribed Twynsta. 
CHMP je ugotovil, da se utegnejo bolniki, ki že jemljejo zdravilni učinkovini v ločenih tabletah, lažje držati zdravljenja, če se jim predpiše zdravilo Twynsta.
Studies were also carried to show that Twynsta tablets are absorbed in the same way in the body as separate tablets of amlodipine and telmisartan. 
Izvedene so bile tudi študije, ki kažejo, da se zdravilo Twynsta v telesu enako absorbira kot ločeni tableti amlodipina in telmisartana.
Twynsta is taken by mouth as one tablet once a day and is used for long-term treatment. 
Zdravilo Twynsta se jemlje peroralno, in sicer ena tableta na dan, ter je namenjeno dolgotrajnemu zdravljenju.
Twynsta must not be used in patients who have severe liver or bile problems, shock (a steep fall in blood pressure), obstruction to blood flow from the left side of their heart or in patients with heart failure after having a myocardial infarction (heart attack). 
Prav tako ga ne smejo uporabljati bolniki s hudimi obolenji jeter ali žolčnika, bolniki, ki so doživeli šok (nagel, močan padec krvnega tlaka), bolniki z zaporo pretoka krvi na levi strani srca oziroma bolniki s srčnim popuščanjem po miokardnem infarktu (srčnem napadu).
In two other main studies, 1,978 adults whose hypertension had not responded adequately to amlodipine were either given Twynsta or continued to take amlodipine at the same or a higher dose. 
V dveh drugih glavnih študijah je 1 978 odraslih, pri katerih visok krvni tlak ni bil ustrezno uravnan zgolj z amlodipinom, prejemalo zdravilo Twynsta ali nadaljevalo jemanje amlodipina v enakem ali višjem odmerku.
For the full list of all side effects reported with Twynsta, see the package leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Twynsta, glejte navodilo za uporabo.
In one main study, 1,461 adults with hypertension were treated with combinations of telmisartan and amlodipine, with telmisartan or amlodipine alone, or with placebo (a dummy treatment). 
V eni glavni študiji je 1 461 odraslih s hipertenzijo jemalo kombinacijo telmisartana in amlodipina, samo telmisartan ali samo amlodipin ali placebo (zdravilo brez zdravilne učinkovine).
Twynsta must also not be used in combination with aliskiren-containing medicines (also used to treat essential hypertension) in patients with type 2 diabetes or in patients with moderate or severe kidney impairment. 
Zdravilo Twynsta se prav tako ne sme uporabljati v kombinaciji z zdravili, ki vsebujejo aliskiren (ki se uporablja za zdravljenje esencialne hipertenzije), pri bolnikih s sladkorno boleznijo tipa 2 ali zmerno do hudo ledvično okvaro.
In the first study, the falls in diastolic blood pressure seen in patients taking combinations of telmisartan and amlodipine were greater than those seen in patients taking only one of the active substances or placebo. 
V prvi študiji je bilo znižanje diastoličnega krvnega tlaka, opaženo pri bolnikih, ki so jemali kombinacijo telmisartana in amlodipina, večje kot pri bolnikih, ki so jemali samo eno od obeh zdravilnih učinkovin ali placebo.
In the two other studies, Twynsta was more effective at reducing diastolic blood pressure than continued treatment with amlodipine alone: depending on the strengths of Twynsta and amlodipine, the fall in diastolic blood pressure was greater in patients taking Twynsta by between 1.4 mmHg and 4.9 mmHg. 
V dveh drugih študijah je bilo zdravilo Twynsta pri zniževanju diastoličnega krvnega tlaka učinkovitejše od neprekinjenega zdravljenja zgolj z amlodipinom: zmanjšanje diastoličnega krvnega tlaka je bilo večje pri bolnikih, ki so jemali zdravilo Twynsta, in sicer med 1,4 mmHg in 4,9 mmHg, odvisno od uporabljene jakosti tega zdravila.
What is the risk associated with Twynsta? 
Kakšna tveganja so povezana z zdravilom Twynsta?
Why has Twynsta been approved? 
Zakaj je bilo zdravilo Twynsta odobreno?
For a patient who has been taking telmisartan and amlodipine as separate tablets, the dose of Twynsta to be taken depends on the doses of telmisartan and amlodipine that he or she was taking before. 
Pri bolnikih, ki so jemali telmisartan in amlodipin kot ločeni tableti, je odmerek zdravila Twynsta odvisen od odmerkov telmisartana in amlodipina, ki so jih jemali prej.
By blocking the receptors to which angiotensin II normally attaches, Telmisartan stops the hormone having an effect, allowing the blood vessels to widen. 
Telmisartan z zaviranjem receptorjev, na katere se angiotenzin II običajno veže, prepreči učinek hormona, kar privede do razširitve žil.
Twynsta can also be used in place of treatment with telmisartan and amlodipine in patients who are taking both medicines as separate tablets. 
Lahko se uporablja tudi namesto zdravljenja s telmisartanom in amlodipinom pri bolnikih, ki ti učinkovini jemljejo kot ločeni tableti.
Twynsta is used in patients whose blood pressure is not adequately controlled by amlodipine alone. 
Zdravilo Twynsta se uporablja pri bolnikih, pri katerih visok krvni tlak ni zadostno uravnan zgolj z amlodipinom.
When appropriate, direct switch to Twynsta may be considered. 
Možen je tudi neposreden prehod na zdravilo Twynsta, kadar se to izkaže kot ustrezno.
Twynsta is a medicine that contains two active substances, telmisartan and amlodipine. 
Twynsta je zdravilo, ki vsebuje dve zdravilni učinkovini, telmisartan in amlodipin.
For a patient whose blood pressure is not adequately controlled by amlodipine, separate tablets of amlodipine and telmisartan should be used to adjust the doses before switching to Twynsta. 
Pri bolnikih, pri katerih krvni tlak ni zadostno uravnan z amlodipinom, je treba pred prehodom na zdravilo Twynsta za prilagoditev odmerka uporabiti ločene tablete amlodipina in telmisartana.
Twynsta contains two active substances, telmisartan and amlodipine. 
Zdravilo Twynsta vsebuje dve zdravilni učinkovini, telmisartan in amlodipin.
What is Twynsta used for? 
Za kaj se zdravilo Twynsta uporablja?
How has Twynsta been studied? 
Kako je bilo zdravilo Twynsta raziskano?
What is Twynsta? 
Kaj je zdravilo Twynsta?
How is Twynsta used? 
Kako se zdravilo Twynsta uporablja?
How does Twynsta work? 
Kako zdravilo Twynsta deluje?
ATCvet code: QI06AH09. 
Oznaka ATCvet: QI06AH09.
Date of first authorisation: 23/02/2005 Date of last renewal: 25/01/2010 
Datum pridobitve dovoljenja za promet: 23/02/2005 Datum podaljšanja dovoljenja za promet: 25/01/2010
69800 Saint-Priest 
F-69800 Saint Priest
Manufacturer responsible for the batch release: MERIAL 
Izdelovalec, odgovoren za sproščanje serij: MERIAL
1 cell culture infective dose 50%. 
1 50% infektivni odmerek za celično kulturo
Name and address of the manufacturers of the biological active substances 
Ime in naslov izdelovalcev biološkihzdravilnih učinkovin:
Where high levels of maternal antibodies against rhinotracheitis, calicivirosis or panleucopenia components are expected to be present (e.g. in kittens of 9-12 weeks of age born from queens which were vaccinated before pregnancy and/or with known or suspected previous exposure to the pathogen(s)), the primary vaccination course should be delayed until 12 weeks of age. 
Kjer je pričakovati visoke titre maternalnih protiteles proti komponentam rinotraheitisa, kalici viroze ali panleukopenije (na primer pri mladičih starih od 9 do 12 tednov, rojenih mačkam, ki so bile cepljene pred brejostjo in/ali je znano ali verjetno, da so bile predhodno izpostavljene patogenu (om)), je potrebno osnovno cepljenje odložiti do starosti 12 tednov.
EU/2/04/052/001 Lyophilisate (10 bottles of 1 dose) + solvent (10 bottles of 1 ml) EU/2/04/052/002 Lyophilisate (50 bottles of 1 dose) + solvent (50 bottles of 1 ml) 
EU/2/04/052/001 Liofilizat (10 stekleničk z 1 odmerkom) in vehikel (10 stekleničk po 1 ml) EU/2/04/052/002 Liofilizat (50 stekleničk z 1 odmerkom) in vehikel (50 stekleničk po 1 ml)
Revaccination: - the first revaccination must be carried out one year after the primary vaccination course, - subsequent revaccinations must be carried out at intervals of up to three years for the rhinotracheitis, calicivirosis and panleucopenia components. 
Ponovno cepljenje: - prvo ponovno cepljenje je potrebno opraviti eno leto po osnovnem cepljenju, - naslednja ponovna cepljenja je potrebno opraviti v obdobjih do 3eh let za komponente kužnega rinotraheitisa, kaliciviroze in panleukopenije.
Water for injection ....................................................................................................................... q.s. 
Voda za injiciranje....................................................................................................................... q.s.
The product was shown to reduce excretion of feline calicivirus at onset of immunity and for one year after vaccination. 
Cepivo dokazano zmanjša izločanje kalici viusa mačk ob nastopu imunosti in do eno leto po cepljenju.
Active immunisation of cats aged 8 weeks and older: - against feline viral rhinotracheitis to reduce clinical signs, - against calicivirus infection to reduce clinical signs, - against feline panleucopenia to prevent mortality and clinical signs. 
Aktivna imunizacija 8 tednov starih mačk in starejših: - proti kužnemu rinotraheitisu mačk, za ublažitev kliničnih znamenj, - proti okužbam s kalicivirusi, za ublažitev kliničnih znamenj, - proti mačji panleukopeniji, za preprečevanje smrtnosti in ublažitev kliničnih znamenj.
FHV (F2 strain) ................................................................................................................. ≥ 104.9 CCID50 FCV (431 and G1 strains) ............................................................................................... ≥ 2.0 ELISA U. FPV (PLI IV) .................................................................................................................... ≥ 103.5 CCID50. 
FHV (sev F2) ...................................................................................................................... ≥ 104,9 CCID50 FCV (seva 431 in G1) ....................................................................................... ≥ 2,0 enot v testu ELISA FPV (PLI IV) ...................................................................................................................... ≥ 103,5 CCID50
Marketing authorisation holder: Boehringer Ingelheim Vetmedica GmbH 55216 Ingelheim/Rhein GERMANY 
Imetnik dovoljenja za promet z zdravilom Boehringer Ingelheim Vetmedica GmbH 55216 Ingelheim/Rhein
A. MANUFACTURERS OF THE BIOLOGICAL ACTIVE SUBSTANCES AND MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE 
A. IZDELOVALCI BIOLOŠKIH ZDRAVILNIH UČINKOVIN IN IMETNIK DOVOLJENJ ZA IZDELAVO ZDRAVILA, ODGOVOREN ZA SPROŠČANJE
Lyophilisate (10x1 dose) + solvent (10x1 ml) Lyophilisate (50x1 dose) + solvent (50x1 ml) 
Liofilizat (10 x 1 odmerek) in vehikel (10 x 1 ml) Liofilizat (50 x 1 odmerek) in vehikel (50 x1 ml)
No effects other than those already mentioned in section 4.6 “Adverse reactions” have been observed, except hyperthermia that may exceptionally last 5 days. 
4.10 Preveliko odmerjanje (simptomi, nujni ukrepi, protistrupi), če je potrebno Drugi učinki, razen tistih, ki so navedeni v poglavju 4.6 »Neželeni učinki«, niso znani, razen povišane temperature , ki izjemoma lahko traja pet dni.
Inject by subcutaneous route one dose (1 ml) of vaccine after reconstitution of the lyophilisate with the solvent, according to the following vaccination schedule: 
Po rekonstituciji liofilizirane sestavine z vehiklom injicirajte odmerek (1 ml) cepiva v podkožje, po naslednjem razporedu:
The duration of immunity after the last re-vaccination is 3 years for rhinotracheitis, calicivirosis and panleucopenia components. 
Trajanje imunosti po zadnjem ponovnem cepljenju je 3 leta za komponente kužnega rinotraheitisa, kalicivirozein mačje panleukopenije.
Stimulates active immunity against feline rhinotracheitis virus, feline calicivirus, and feline panleucopenia virus. 
Vzpodbuja aktivno imunost proti virusu kužnega rinotraheitisa, kalicivirusu in virusu panleukopenije mačk.
PARTICULARS TO APPEAR ON THE OUTER PACKAGE Pack of 10 bottles of lyophilisate and 10 bottles of solvent Pack of 50 bottles of lyophilisate and 50 bottles of solvent 
Vsebnik z 10 stekleničkami liofilizata in 10 stekleničkami vehikla Vsebnik s 50 stekleničkami liofilizata in 50 stekleničkami vehikla
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS Lyophilisate bottle 
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA MANJŠIH STIČNIH OVOJNINAH
Purevax RCP lyophilisate and solvent for suspension for injection 
Purevax RCP liofilizat in vehikel suspenzijo za injiciranje
Attenuated feline rhinotracheitis herpesvirus (FHV F2 strain) ....................................... ≥ 104.9 CCID501 Inactivated feline calicivirus (FCV 431 and G1 strains) antigens ................................... ≥ 2.0 ELISA U. Attenuated feline panleucopenia virus (PLI IV) ............................................................. ≥ 103.5 CCID501 
Inaktivirani antigeni kalici virusa mačk (seva FCV 431 in G1) ....................... ≥ 2,0 enot v testu ELISA Atenuiran virus panleukopenije mačk (PLI IV) .............................................................. ≥ 103,5 CCID501
Vaccine against feline viral rhinotracheitis, feline calicivirosis and feline panleucopenia. 
Cepivo proti virusnemu rinotraheitisu, kalicivirusu in panleukopeniji mačk.
Purevax RCP lyophilisate and solvent for suspension for injection. 
Purevax RCP Liofilizat in vehikel za suspenzijo za injiciranje
No effect other than those already mentioned in section on “Adverse reactions” have been observed after the administration of several doses, except hyperthermia that may exceptionally last 5 days. 
Po večkratnem dajanju drugi učinki, razen tistih ki so navedeni v poglavju »Neželeni učinki«, niso znani.
Attenuated feline rhinotracheitis herpesvirus (FHV F2 strain) ....................................... ≥ 104.9 CCID501 Inactivated feline calicivirus (FCV 431 and FCV G1 strains) antigens .......................... ≥ 2.0 ELISA U. Attenuated feline panleucopenia virus (PLI IV) ............................................................. ≥ 103.5 CCID501 
Inaktivirani antigeni kalici virusa mačk (sev FCV 431 in G1) ......................... ≥ 2,0 enot v testu ELISA
Onsets of immunity have been demonstrated 1 week after primary vaccination course for the rhinotracheitis, calicivirus and panleucopenia components. 
Imunost proti kužnemu rinotraheitisu, kalicivirusu mačk in mačji panleukopeniji nastopi 1 teden po osnovnem cepljenju.
ANNEX II A. MANUFACTURERS OF THE BIOLOGICAL ACTIVE SUBSTANCES AND MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE C. STATEMENT OF THE MRLs 
A. IZDELOVALCI BIOLOŠKIH ZDRAVILNIH UČINKOVIN IN IMETNIK DOVOLJENJ ZA IZDELAVO ZDRAVILA, ODGOVOREN ZA SPROŠČANJE SERIJE
This means that it is similar to a ‘reference medicine' containing the same active substance, but is given in a different way. 
To pomeni, da je podobno referenčnemu zdravilu, ki vsebuje enako zdravilno učinkovino, vendar se daje drugače.
Nyxoid can be used in adults and adolescents from 14 years of age. 
Zdravilo Nyxoid se lahko uporablja pri odraslih in mladostnikih, starejših od 14 let.
The full EPAR for Nyxoid can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Nyxoid je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
What measures are being taken to ensure the safe and effective use of Nyxoid? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Nyxoid?
This is a summary of the European public assessment report (EPAR) for Nyxoid. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Nyxoid.
Therefore, the European Medicines Agency decided that Nyxoid's benefits are greater than its risks and recommended that it be approved for use in the EU. 
Evropska agencija za zdravila je zato zaključila, da so koristi zdravila Nyxoid večje od z njim povezanih tveganj, in priporočila, da se odobri za uporabo v EU.
Nyxoid is a ‘hybrid medicine'. 
Zdravilo Nyxoid je „hibridno zdravilo“.
The company that markets Nyxoid will issue educational materials, including a video, for healthcare professionals and for patients with detailed information on how to use the medicine. 
Družba, ki trži zdravilo Nyxoid, bo izdala izobraževalno gradivo, vključno z videoposnetkom, za zdravstvene delavce in bolnike s podrobnimi informacijami o načinu uporabe zdravila.
Other information about Nyxoid 
Druge informacije o zdravilu Nyxoid
In addition, a study involving 38 healthy volunteers showed that, when given by a healthcare professional, Nyxoid 2 mg given as a spray into the nose produced a similar level of naloxone in the body as naloxone given in the usual dose of 0.4 mg by injection into a muscle. 
Poleg tega so s študijo, ki je vključevala 38 zdravih prostovoljcev, dokazali, da 2-miligramski odmerek zdravila Nyxoid , ki se daje v obliki pršila v nos, proizvede podobno raven naloksona v telesu kot nalokson, ki se daje v običajnem odmerku 0,4 mg z injiciranjem v mišico.
The company will also conduct a study on the effectiveness of Nyxoid when given by people with no medical training. 
Opravila bo tudi študijo o učinkovitosti zdravila Nyxoid, kadar ga dajejo osebe brez medicinskega usposabljanja.
Naloxone rapidly blocks these receptors, ending the opioid's effects such as slow breathing. 
Nalokson hitro zavre te receptorje in prekine učinke opioida, kot je počasno dihanje.
The most common side effect with Nyxoid (which may affect more than 1 in 10 people) is nausea (feeling sick). 
Najpogostejši neželeni učinek zdravila Nyxoid (ki se lahko pojavi pri več kot 1 osebi od 10) je navzeja (siljenje na bruhanje).
There is also no risk of needle injury with Nyxoid, and this could encourage members of the public to provide treatment promptly. 
Pri zdravilu Nyxoid prav tako ni tveganja za poškodbe z iglo, kar bi lahko spodbudilo splošno javnost, da takoj izvede zdravljenje.
Nyxoid is a nasal spray available in single-dose containers (1.8 mg). 
Zdravilo Nyxoid je nosno pršilo, ki je na voljo v enoodmernih vsebnikih (1,8 mg).
Opioids work by attaching to and activating opioid receptors (targets) in the body. 
Opioidi delujejo tako, da se vežejo na opioidne receptorje (prijemališča) v telesu in jih aktivirajo.
If the first dose works well but the patient later worsens a second dose should be given immediately in the other nostril. 
Če prvi odmerek učinkuje, vendar se bolnikovo stanje pozneje poslabša, je treba v drugo nosnico takoj dati drugi odmerek.
It is not intended to provide practical advice on how to use Nyxoid. 
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.